Cancer Family
Malignant Breast Neoplasm
CI-CAN-00000227Explore in graph →
Top-level2,627 active trials43 approved drugs310 evidence items
- NCIt
- C9335
- ICD-10
- C50
- DOID
- 1612
- Other
- 2 more codes
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000227Explore in graph →
Clinical trials
12,360 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,368)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02284919 | [18F]ISO-1 Positron Emission Tomography (PET/CT) in Primary Breast Cancer(ISO-1Primary) | active not recruiting | Phase 1 | 30 | University of PennsylvaniaOTHER | 1 | Jan 9, 2026 | clinicaltrials |
| NCT04630080 | Alopecia Prevention Scalp Cooling in Chinese Breast Cancer Patients | active not recruiting | N/A | 25 | Chinese University of Hong KongOTHER | 1 | Jan 9, 2026 | clinicaltrials |
| NCT00588029 | Collection of Tissue, Blood, and Cells to Be Used For Studying the Causes, Prevention, Diagnosis, and Treatment of Breast Cancer | active not recruiting | — | 7,000 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT04290793 | Neoadjuvant Chemotherapy With Pyrotinib, Epirubicin and Cyclophosphamide Followed by Taxanes and Trastuzumab for HER-2+ Breast Cancer | active not recruiting | Phase 2 / Phase 3 | 113 | Hebei Medical University Fourth HospitalOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT04872985 | Pyrotinib Plus Neoadjuvant Chemotherapy in HR+/HER2-, HER4-High Breast Cancer | active not recruiting | Phase 2 | 140 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT05544929 | A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers | active not recruiting | Phase 1 | 126 | Novartis PharmaceuticalsINDUSTRY | 12 | Jan 6, 2026 | clinicaltrials |
| NCT01196936 | Low-Dose Tamoxifen Citrate in Reducing Breast Cancer Risk in Radiation-Induced Cancer Survivors(LDTam) | active not recruiting | Phase 2 | 84 | University of Alabama at BirminghamOTHER | 2 | Jan 5, 2026 | clinicaltrials |
| NCT03344965 | Olaparib In Metastatic Breast Cancer | active not recruiting | Phase 2 | 114 | Beth Israel Deaconess Medical CenterOTHER | 1 | Jan 5, 2026 | clinicaltrials |
| NCT05023967 | Metformin and Nightly Fasting in Women With Early Breast Cancer | active not recruiting | Phase 2 | 120 | M.D. Anderson Cancer CenterOTHER | 2 | Jan 5, 2026 | clinicaltrials |
| NCT06418126 | Prediction of Radiotherapy Efficacy in Patients With Triple-negative Breast Cancer(TNBC-RT2023) | active not recruiting | N/A | 15 | Centre Paul StraussOTHER | 1 | Jan 5, 2026 | clinicaltrials |
| NCT07316439 | Comparison Between ER Loss and Triple-Negative Breast Cancer Guided by 18F-FES PET/CT in Metastatic Breast Cancer | active not recruiting | — | 197 | Fudan UniversityOTHER | 1 | Jan 5, 2026 | clinicaltrials |
| NCT07317765 | Research on New Methods and New Models of Rehabilitation Intervention for Cancer Patients Based on Exercise and Psychological Intervention | active not recruiting | N/A | 200 | Beijing HuiLongGuan HospitalOTHER | 1 | Jan 5, 2026 | clinicaltrials |
| NCT03090165 | Ribociclib and Bicalutamide in AR+ TNBC | active not recruiting | Phase 1 / Phase 2 | 37 | Kari WisinskiOTHER | 1 | Jan 2, 2026 | clinicaltrials |
| NCT03393845 | Study of Pembrolizumab Plus Fulvestrant in Hormone Receptor Positive, HER-2 Negative Advanced/Metastatic Breast Cancer Patients | active not recruiting | Phase 2 | 47 | Nancy Chan, MDOTHER | 1 | Jan 2, 2026 | clinicaltrials |
| NCT04762979 | Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer | active not recruiting | Phase 2 | 44 | Marina N SharifiOTHER | 1 | Jan 2, 2026 | clinicaltrials |
| NCT04141449 | A Multilevel Intervention to Improve Timely Cancer Detection and Treatment Initiation(Potlako+) | active not recruiting | Phase 2 | 874 | Brigham and Women's HospitalOTHER | 1 | Dec 31, 2025 | clinicaltrials |
| NCT02051218 | Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks | active not recruiting | Phase 3 | 1,380 | Swiss Cancer InstituteOTHER | 3 | Dec 30, 2025 | clinicaltrials |
| NCT02276885 | Prone Partial Breast Irradiation (PBI): a Prospective Randomized Trial | active not recruiting | N/A | 284 | NYU Langone HealthOTHER | 1 | Dec 30, 2025 | clinicaltrials |
| NCT07311278 | Identification of Sentinel Lymph Nodes Using Indocyanine Green in Breast Cancer Patients(INFLUENCE II) | active not recruiting | N/A | 493 | St. Antonius HospitalOTHER | 2 | Dec 30, 2025 | clinicaltrials |
| NCT04989179 | Incidence and Factors Affecting the Development and Outcome of Post Mastectomy Pain Syndrome(PMPS) | active not recruiting | — | 220 | Singapore General HospitalOTHER | 1 | Dec 26, 2025 | clinicaltrials |
| NCT05278741 | Functional Evaluation After Breast Reconstruction With a Minimally Invasive Latissimus Dorsi Flap Following Radical Surgery for Breast Cancer.(BREAST) | active not recruiting | N/A | 32 | Centre Georges Francois LeclercOTHER | 1 | Dec 26, 2025 | clinicaltrials |
| NCT03892655 | Real World Study of Biosimilar Trastuzumab in Her2 Positive Breast Cancer(LB1802) | active not recruiting | — | 170 | Libbs Farmacêutica LTDAINDUSTRY | 1 | Dec 24, 2025 | clinicaltrials |
| NCT05305365 | Study Assessing QBS72S For Treating Brain Metastases | active not recruiting | Phase 2 | 21 | Stanford UniversityOTHER | 1 | Dec 23, 2025 | clinicaltrials |
| NCT03285412 | CDK 4/6 Inhibitor, Ribociclib, With Adjuvant Endocrine Therapy for ER-positive Breast Cancer(LEADER) | active not recruiting | Phase 2 | 120 | Massachusetts General HospitalOTHER | 1 | Dec 22, 2025 | clinicaltrials |
| NCT03997123 | Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC(CAPItello-290) | active not recruiting | Phase 3 | 923 | AstraZenecaINDUSTRY | 30 | Dec 22, 2025 | clinicaltrials |
| NCT04537312 | Prospective Pilot Study of Robot-assisted Nipple Sparing Mastectomy (RNSM) | active not recruiting | N/A | 4 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Dec 22, 2025 | clinicaltrials |
| NCT02050750 | TAILORx Tissue Bank | active not recruiting | — | 600 | Cancer Trials IrelandNETWORK | 1 | Dec 19, 2025 | clinicaltrials |
| NCT02352883 | MRI and Gene Expression in Diagnosing Patients With Ductal Breast Cancer In Situ | active not recruiting | N/A | 368 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Dec 19, 2025 | clinicaltrials |
| NCT03818087 | Elevate! : An Elderly Breast Cancer Cohort Study | active not recruiting | — | 253 | Dana-Farber Cancer InstituteOTHER | 1 | Dec 19, 2025 | clinicaltrials |
| NCT07293052 | Comparison of Outcome Between Grisotti Flap Versus Reverse Mirror Grisotti Flap for Central Quadrant Breast Tumors(GRISOTTI FLAP) | active not recruiting | N/A | 106 | Mayo Hospital LahoreOTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT04532177 | Stereotactic Body Radiation Therapy (SBRT) for Invasive Breast Cancer Patients Not Undergoing Definitive Surgery(SBRT BREAST) | active not recruiting | N/A | 15 | Stony Brook UniversityOTHER | 1 | Dec 17, 2025 | clinicaltrials |
| NCT06397651 | A Randomised Controlled Trial to Evaluate the Impact of Complement Theory's Live CoActive Exercise Coaching and Personalized Digital Application on Cancer Survivors' Quality of Life | active not recruiting | N/A | 146 | Complement Theory Inc.INDUSTRY | 1 | Dec 17, 2025 | clinicaltrials |
| NCT02755896 | Trial to Compare Radiation Fibrosis With Five Versus Three Fractions | active not recruiting | Phase 2 | 350 | Weill Medical College of Cornell UniversityOTHER | 1 | Dec 15, 2025 | clinicaltrials |
| NCT04745754 | The Engaging Primary Care in Cancer Survivorship (EPICS) Study(EPICS) | active not recruiting | N/A | 2,450 | Kaiser PermanenteOTHER | 1 | Dec 12, 2025 | clinicaltrials |
| NCT04379414 | YES Study - Newly Diagnosed/Metastatic Intervention(YES) | active not recruiting | N/A | 400 | Dana-Farber Cancer InstituteOTHER | 1 | Dec 9, 2025 | clinicaltrials |
| NCT04538742 | A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer(DB-07) | active not recruiting | Phase 1 / Phase 2 | 245 | AstraZenecaINDUSTRY | 15 | Dec 8, 2025 | clinicaltrials |
| NCT04661982 | Long Term Follow-Up in Patients With Stage 0-IIIC Breast Cancer | active not recruiting | — | 500 | City of Hope Medical CenterOTHER | 1 | Dec 5, 2025 | clinicaltrials |
| NCT06612203 | Clinical Study to Evaluate Debio0123 + Sacituzumab Govitecan Combination in TNBC or HR+/HER2- Advanced Breast Cancer(WIN-B) | active not recruiting | Phase 1 / Phase 2 | 76 | MedSIROTHER | 2 | Dec 5, 2025 | clinicaltrials |
| NCT04438681 | Evaluation of a Plasma Protein Profile as a Predictive Biomarker for Metastatic Relapse in Triple Negative Breast Cancer Patients(INSTIGO) | active not recruiting | — | 90 | Centre Jean PerrinOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT05410951 | LobularCard Trial: Searching for Novel Germline Mutations in Lobular Breast Cancer Patients(LobularCard) | active not recruiting | — | 800 | European Institute of OncologyOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT03983954 | Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer. | active not recruiting | Phase 1 | 120 | NeoTX Therapeutics Ltd.INDUSTRY | 2 | Nov 28, 2025 | clinicaltrials |
| NCT01898117 | Triple-B Study;Carboplatin-cyclophosphamide Versus Paclitaxel With or Without Atezolizumab as First-line Treatment in Advanced Triple Negative Breast Cancer(Triple-B) | active not recruiting | Phase 2 | 304 | The Netherlands Cancer InstituteOTHER | 1 | Nov 26, 2025 | clinicaltrials |
| NCT03143322 | Standard Treatment +/- SBRT in Solid Tumors Patients With Between 1 and 5 Bone-only Metastases(STEREO-OS) | active not recruiting | N/A | 168 | UNICANCEROTHER | 1 | Nov 26, 2025 | clinicaltrials |
| NCT03571633 | Impact of Pegfilgrastim on Trastuzumab Anti-tumor Effect and ADCC in Operable HER2+ Breast Cancer Breast Cancer(BREASTIMMU02) | active not recruiting | Phase 2 | 90 | Centre Leon BerardOTHER | 1 | Nov 26, 2025 | clinicaltrials |
| NCT04193059 | Study Comparing EC-T Verses PCb in the Adjuvant Chemotherapy of Non-triple Negative Breast Cancer(PANSY) | active not recruiting | Phase 3 | 1,560 | Fudan UniversityOTHER | 1 | Nov 26, 2025 | clinicaltrials |
| NCT06495164 | A Real-life Study to Understand the Use and Effects of Palbociclib in US Patients With Breast Cancer | active not recruiting | — | 1 | PfizerINDUSTRY | 1 | Nov 25, 2025 | clinicaltrials |
| NCT01516190 | The Preoperative Health & Body Study(PreHab) | active not recruiting | N/A | 49 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT03657628 | Physical Activity, Proliferation and Immune Markers in Benign Breast Tissue | active not recruiting | N/A | 60 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT05266105 | A Phase 1 Study of Oral OP-1250 in Combination With Palbociclib in HR+/HER2- Breast Cancer Patients | active not recruiting | Phase 1 | 60 | Olema Pharmaceuticals, Inc.INDUSTRY | 1 | Nov 24, 2025 | clinicaltrials |
| NCT06572774 | Community Clinic Model to Improve Early Detection of Breast and Cervical Cancers in Kenya(C3Link) | active not recruiting | N/A | 5,400 | ImplenomicsOTHER | 1 | Nov 24, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Jan 9, 2026source: clinicaltrials